Psyomics Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Psyomics Ltd. - overview
Established
2015
Location
Cambridge, -, UK
Primary Industry
Healthcare Specialists
About
Founded in 2015 by Sabine Bahn (CMO) and others and based in Cambridge, UK, Psyomics Ltd. operates as a developer of proteomic diagnostics treatment for mental health patients. In March 2024, Psyomics Ltd. raised GBP 3.
7 million in venture funding from Parkwalk Advisors. The March 2024 financing values Psyomics Ltd. at GBP 12. 21 million post-money.
As of 2024, the company is led by its CEO, Melinda Rees. The company provides its primary product, Censeo, which is a web-based medical device designed for mental health triage and assessment. Censeo enhances clinical decision-making accuracy and increases efficiency by streamlining the mental health assessment process. The organization plans to use the March 2024 funding to enhance its AI-enabled medical device, Censeo.
Current Investors
Cambridge Enterprise, Parkwalk Advisors, Martlet Capital
Primary Industry
Healthcare Specialists
Sub Industries
Clinics/Outpatient Services, Healthcare IT, Mental Health Services
Website
www.psyomics.com/
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.